Clinicopathological, Genetic and Survival Advantages of Naevus-associated Melanomas: A Cohort Study

Xavier BOSCH-AMATE1, Sebastian PODLIPNIK1,2, Constanza RIQUELME-MC LOUGHLIN1, Cristina CARRERA1–3, Alicia BARREIRO-CAPURRO1, Adriana GARCIA-HERRERA4, Llucia ALOS4, Josep MALVEHY1–3 and Susana PUIG1–3

1Dermatology Department, Hospital Clinic of Barcelona, University of Barcelona, 2Melanoma Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 3Biomedical Research Networking Center on Rare Diseases (CIBERER), ISCIII and 4Pathology Department, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain

Several studies have suggested that naevus-associated melanomas differ from de novo melanomas, being thinner and with less ulceration; however, the prognostic implication is unclear. The objective of this study was to describe clinicopathological, genetic and survival characteristics of de novo and naevus-associated melanomas in a cohort of primary invasive cutaneous melanomas over a 20-year period. Of the 2,227 patients included in the study, 509 (22.86%) had naevus-associated melanomas. Compared with patients with de novo melanoma, they were younger, with a fairer phototype and a higher naevus count, tumours were predominantly the superficial spreading subtype, American Joint Committee on Cancer stage I, located on the trunk, and there were fewer signs of invasiveness (thinner Breslow index, less ulceration, lower mitotic index and less satellitosis). Germline mutational status did not show any significant association. As determined through univariate analysis, overall survival was significantly better in patients with naevus-associated melanoma (hazard ratio 0.64; 95% confidence interval 0.51–0.80, p < 0.001), but multivariate analysis did not support this prognostic indication (hazard ratio 0.94; 95% confidence interval 0.75–1.18, p < 0.606). Despite this, we conclude that naevus-associated and de novo melanomas should be considered as different subtypes of melanoma.

Key words: melanoma; naevus-associated; de novo; histopathological; genetic; prognosis; survival.

Accepted Feb 25, 2021; Epub ahead of print Mar 9, 2021
Acta Derm Venereol 2021; 101: adv00425.

Corr.: Susana Puig, Melanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Villarroel 170, ES-08036, Barcelona, Spain. E-mails: susipuig@gmail.com, spuig@clinic.cat, susipuig@ub.edu

The incidence of cutaneous melanoma is increasing worldwide (1, 2). In addition, it is an important healthcare problem, since it is one of the most frequent types of cancer affecting young adults (3).

To date, little is known about patient and/or tumour factors that give rise to melanoma in normal skin or in association with a naevus. In 1978, Clark proposed a carcinogenic evolution from dysplastic naevi to melanoma in patients with a family history of melanoma (4). However, the significance of this claim remains uncertain, as benign acquired naevi can also be found in association with melanomas, and not all melanomas appear from precursor lesions. Histopathological studies have revealed naevus-associated cells in approximately 10–50% of melanomas, and only 40–50% of these naevus cells had dysplastic features (5–11). In addition, it appears that the majority of melanomas arise de novo and not from precursor lesions (6, 12).

Naevus-associated melanomas (NAM) are more often of the superficial spreading subtype, affect young patients, are located on the trunk, have a thinner Breslow index, and absence of ulceration (5–9, 11, 13, 14). However, it remains unclear if there is a survival advantage in NAM compared with de novo melanomas (DNM) or if there are genetic differences between them (9, 13, 15).

The primary objective of this study was to examine both overall survival (OS) and melanoma-specific survival (MSS) in NAM compared with DNM. A secondary objective was to analyse the clinicopathological and genetic background of the tumours and patients by germline mutations in susceptibility genes, from a large cohort of prospectively followed patients with melanoma.

MATERIALS AND METHODS

Study design and setting

This cohort study included patients with melanoma seen at Hospital Clinic of Barcelona, Spain from January 1998 through December 2017. All variables were prospectively recorded, following the staging and follow-up protocols, in our centre (16, 17). This registry mainly includes patients of Mediterranean origin, living
in the Catalonia region. Written informed consent was obtained from all patients. The study was approved by the Clinical Research Ethics Committee of Hospital Clinic of Barcelona (institutional review board number HCB/2015/0298). This study was performed following the 2015 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (18).

Participants and variables
As eligibility criteria, all patients diagnosed with invasive primary cutaneous melanomas without distant disease were included. If a patient had more than one melanoma, the one with worst prognosis, characterized by the highest American Joint Committee on Cancer (AJCC) stage, was included in the statistical analysis. Exclusion criteria were: patients with stage IV at the time of diagnosis (to avoid bias in survival); those with missing data that prevented a proper staging; patients who did not continue follow-up at our centre; and patients whose histology was not prospectively recorded in our database (Fig. 1).

The main outcome variable was overall survival, defined as the length of time from primary melanoma diagnosis to the date of death by any cause or last follow-up visit. The secondary outcome variable was melanoma-specific survival, calculated from the time of diagnosis of the primary melanoma to the time of death by melanoma or the last follow-up visit.

As independent variables, we prospectively included the patients’ demographic (age, sex, and clinical (Fitzpatrick skin type, naevus count, eye and hair colour) characteristics. In addition, the tumour’s location (and number of primary tumours) with the histopathological (histological subtype, Breslow index, ulceration status, miotic index, presence of satellitosis and regression) and sentinel lymph node biopsy (SLNB) status were included, thus allowing the staging of the patient following the 8th edition of the AJCC guidelines. Histopathological variables were discussed in a weekly melanoma committee meeting of dermatologists and pathologists. The germline mutational status of MC1R gene was also recorded when present.

Statistical analysis
To determine which of the independent variables were associated with DNM or NAM Pearson’s $\chi^2$ test was used for categorical variables and trend test for ordinal variables. The linear model analysis of variance (ANOVA) was used to compare continuous independent variables.

Survival curves based on Kaplan–Meier methods were used to investigate differences in OS and MSS between de novo and naevus-associated melanomas. Curves were calculated using the “survfit” function in the “survival” package (v 3.1-12) and plotted with the “survminer” package (v 0.4.6) in R (19–21). A log-rank test was performed to test for a significant difference in outcome between the groups.

Univariate and multivariate survival analyses were performed using Cox’s proportional hazards model. Models were fitted using the “coxph” function in the “survival” package (v 3.1-12) in R. Hazard ratio (HR) estimations were calculated for the effect of DNM or NAM on OS and MSS, adjusted for age at diagnosis, sex, AJCC stages and location of the primary tumour. The AJCC classification was used in the multivariate analysis since it includes the main prognostic factors (Breslow index, ulceration and SLNB status) and avoids multicollinearity. A Cox regression table for univariate and multivariate hazard ratios was calculated for better visualization of the data (22).

All statistical tests were 2-sided and a $p$-value ≤ 0.05 was considered significant. All statistical analyses were performed using the computing environment R (v 4.0.0) (23).

RESULTS
Data were available for 3,544 patients, but after applying exclusion criteria, a total of 2,227 patients were included for analysis. The median follow-up time of the cohort was 7.05 years (interquartile range (IQR) 3.2–13.9) (Fig. 1). Of the 2,227 melanomas, 509 were NAM (22.86%). The clinicopathological characteristics of the cohort are summarized in Table 1.

The stratified analysis between NAM and DNM showed that NAM was related to younger age at presentation (49 vs 55 years, $p<0.001$), but without a sex predominance. Phenotypically, it was observed that patients with NAM had fairer skin types, more frequently exhibited blond-red hair colour (29.1% vs 23.5%, $p=0.018$), a higher naevus count (52.2% vs 36.7%, $p<0.001$) and presented more frequently in the setting of multiple primary melanomas (16.7% vs 12.6%, $p=0.019$). The histopathological assessment of the tumours showed that NAM were predominantly the superficial spreading subtype (80.7% vs 66.4%, $p<0.001$) and showed a lower criterion of invasiveness with a Breslow index that was 0.67 mm thinner (1.55 vs 2.22, $p<0.001$) and they were less proportionally ulcerated (13% vs 23.2%, $p<0.001$). As a result, a higher proportion of stage I melanomas (72.5% vs 60.3%, $p<0.001$) was observed in the NAM group. Of 2,227 patients included, 1,027 did not undertake an SLNB. Of these, in 814 (79.3%) cases it was not indicated based on tumour thickness and in 213 (20.7%) was medically indicated, but not performed, due to individual factors. Finally, the stratified analysis of MC1R germline mutations did not show statistically significant differences between the groups (Table 1).

Survival analysis based on Kaplan–Meier curves revealed that NAM had statistically significant higher OS and MSS rates than DNM (Fig. 2). Five-year OS in DNM and NAM was 82% (95% CI 80.1–84) and 88.4% (95% CI 85.5–91.4), respectively. Ten-year OS in DNM and NAM was 71.9% (95% CI 69.5–74.5) and 79.2% (95% CI 75.2–83.5), respectively. Five-year MSS in DNM and
Characteristics of naevus-associated melanomas

|                         | De novo melanoma (n = 1,718) | Naevus-associated melanoma (n = 509) | Total (n = 2,227) | p-value |
|-------------------------|-------------------------------|-------------------------------------|-------------------|---------|
| Age, years, mean (SD)   | 55.74 (17.27)                | 49.13 (16.76)                       | 54.23 (17.38)     | <0.001  |
| Sex, n (%)              |                               |                                     |                   | 0.444   |
| Female                  | 904 (52.6)                    | 258 (50.7)                          | 1,162 (52.2)      |         |
| Male                    | 814 (47.4)                    | 251 (49.3)                          | 1,065 (47.8)      |         |
| Eye colour, n (%)       |                               |                                     |                   | 0.312   |
| Brown-black             | 869 (62.4)                    | 248 (57.8)                          | 1,117 (61.3)      |         |
| Green                   | 271 (19.5)                    | 89 (20.7)                           | 360 (19.8)        |         |
| Blue                    | 238 (17.1)                    | 88 (20.5)                           | 326 (17.9)        |         |
| Other                   | 14 (1.0)                      | 4 (0.9)                             | 18 (1.0)          |         |
| Missing values          | 326                            | 80                                  | 406               |         |
| Hair colour, n (%)      |                               |                                     |                   | 0.018   |
| Brown-black             | 1,063 (76.5)                  | 307 (70.9)                          | 1,370 (75.2)      |         |
| Blond-red               | 326 (23.5)                    | 126 (29.1)                          | 452 (24.8)        |         |
| Missing values          | 329                            | 76                                  | 405               |         |
| Fitzpatrick skin type, n (%) |                      |                                     |                   | <0.001  |
| I                       | 62 (4.4)                      | 23 (5.2)                            | 85 (4.6)          |         |
| II                      | 594 (41.9)                    | 226 (50.7)                          | 820 (44.0)        |         |
| III                     | 604 (42.6)                    | 166 (37.2)                          | 770 (41.3)        |         |
| IV–VI                   | 158 (11.1)                    | 31 (7.0)                            | 189 (10.1)        |         |
| Missing values          | 300                            | 63                                  | 363               |         |
| Naevus count, n (%)     |                               |                                     |                   | <0.001  |
| < 50                    | 647 (63.3)                    | 179 (47.9)                          | 826 (59.2)        |         |
| 51–100                  | 223 (21.8)                    | 108 (28.9)                          | 331 (23.7)        |         |
| > 100                   | 152 (14.9)                    | 87 (23.3)                           | 239 (17.1)        |         |
| Missing values          | 696                            | 135                                 | 831               |         |
| Histological subtype, n (%) |                         |                                     |                   | <0.001  |
| Superficial spreading   | 1,141 (66.4)                  | 411 (80.7)                          | 1,552 (69.7)      |         |
| Nodular                 | 271 (15.8)                    | 44 (8.6)                            | 315 (14.1)        |         |
| Acral lentiginous       | 105 (6.1)                     | 10 (2.0)                            | 115 (5.2)         |         |
| Lentiginous malignant   | 90 (5.2)                      | 6 (1.2)                             | 96 (4.3)          |         |
| Other                   | 111 (6.5)                     | 38 (7.5)                            | 149 (6.7)         |         |
| Melanoma location, n (%)|                               |                                     |                   | <0.001  |
| Trunk                   | 757 (44.1)                    | 310 (60.9)                          | 1,067 (47.9)      |         |
| Lower limbs             | 376 (21.9)                    | 82 (16.1)                           | 458 (20.6)        |         |
| Upper limbs             | 233 (13.6)                    | 49 (9.6)                            | 282 (12.7)        |         |
| Head and neck           | 209 (12.2)                    | 49 (9.6)                            | 258 (11.6)        |         |
| Acral                   | 143 (8.3)                     | 19 (3.7)                            | 162 (7.3)         |         |
| Number of primary melanomas, n (%) |               |                                     |                   | 0.019   |
| Single                  | 1,501 (87.4)                  | 424 (83.3)                          | 1,925 (86.4)      |         |
| Multiple                | 217 (12.6)                    | 85 (16.7)                           | 302 (13.6)        |         |
| Breslow index, median (IQR) | 1.19 (0.65–2.60)            | 1.00 (0.60–1.70)                    | 1.10 (0.63–2.30)  | <0.001  |
| Ulceration, n (%)       |                               |                                     |                   | <0.001  |
| Absent                 | 1,320 (76.8)                  | 443 (87.0)                          | 1,763 (79.2)      |         |
| Present                | 396 (23.2)                    | 66 (13.0)                           | 464 (20.8)        |         |
| Mitotic index, mean (SD) | 2.35 (4.69)                  | 1.70 (3.17)                         | 2.21 (4.41)       | 0.006   |
| Missing values, n       | 119                            |                                     | 179               |         |
| Satellitosis, n (%)     |                               |                                     |                   | 0.010   |
| Absent                 | 1,591 (97.7)                  | 444 (99.6)                          | 2,035 (98.1)      |         |
| Present                | 38 (2.3)                      | 2 (0.4)                             | 40 (1.9)          |         |
| Regression, n (%)       |                               |                                     |                   | 0.002   |
| <50%                   | 324 (32.1)                    | 130 (37.4)                          | 454 (33.5)        |         |
| >50%                   | 143 (14.2)                    | 68 (19.5)                           | 211 (15.5)        |         |
| None                   | 542 (53.7)                    | 150 (43.1)                          | 692 (51.0)        |         |
| Missing values          | 709                            | 161                                 | 870               |         |
| AJCC 8th edition, n (%) |                               |                                     |                   | <0.001  |
| IA                     | 745 (43.4)                    | 251 (49.3)                          | 996 (44.7)        |         |
| IB                     | 291 (16.9)                    | 118 (23.2)                          | 409 (18.4)        |         |
| IIA                    | 165 (9.6)                     | 39 (7.7)                            | 204 (9.2)         |         |
| IIB                    | 141 (8.2)                     | 17 (3.3)                            | 158 (7.1)         |         |
| IIC                    | 65 (3.8)                      | 6 (1.2)                             | 71 (3.2)          |         |
| IIIA                   | 51 (3.0)                      | 21 (4.1)                            | 72 (3.2)          |         |
| IIIB                   | 61 (3.6)                      | 20 (3.9)                            | 81 (3.6)          |         |
| IIIC                   | 183 (10.7)                    | 33 (6.5)                            | 216 (9.7)         |         |
| IIID                   | 16 (0.9)                      | 4 (0.8)                             | 20 (0.9)          |         |
| SLNB status, n (%)     |                               |                                     |                   | 0.349   |
| Negative               | 694 (74.7)                    | 210 (77.5)                          | 904 (75.3)        |         |
| Positive               | 235 (25.3)                    | 61 (22.5)                           | 296 (24.7)        |         |
| Not performed          | 789                            | 238                                 | 1,027             |         |
| MC1R status, n (%)     |                               |                                     |                   | 0.910   |
| Variants               | 444 (68.5)                    | 171 (68.1)                          | 615 (68.4)        |         |
| Wild-type              | 204 (31.5)                    | 80 (31.9)                           | 284 (31.6)        |         |
| Not performed          | 1,070                          | 258                                 | 1,328             |         |

AJCC: American Joint Committee on Cancer; IQR: interquartile range; MC1R: melanocortin 1 receptor; SLNB: sentinel lymph node biopsy; SD: standard deviation.
NAM was 86.5% (95% CI 84.7–88.3) and 90.9% (95% CI 88.3–93.6), respectively. Ten-year MSS in DNM and NAM was 80.9% (95% CI 78.7–83.1) and 86.3% (95% CI 82.9–89.8), respectively.

Univariate Cox regression analysis of OS showed that NAM was associated with a better prognosis than DNM (HR 0.64, 95% CI 0.51–0.80, \( p < 0.001 \)). Similarly, the univariate Cox regression model of MSS showed a protective factor in NAM compared with DNM (HR 0.67, 95% CI 0.50–0.89, \( p = 0.005 \)). However, multivariate Cox regression analysis including all the independent variables in the same model did not show any statistical differences in OS (HR 0.94, 95% CI 0.75–1.18, \( p < 0.606 \)) and MSS (HR 0.88, 95% CI 0.66–1.18, \( p < 0.391 \)) between NAM and DNM (Table II).

### DISCUSSION

This study examined whether NAM and DNMs could be separated into 2 distinct entities with different clinico-pathological, genetic and prognostic features.

In the study cohort, 22.86% of melanomas were NAM, showing a slightly lower percentage compared with a recent meta-analysis by Pampena et al. (6) (29.1%). This could be explained because all the melanoma histological subtypes and body locations were included in the analysis, unlike some studies cited in the meta-analysis, which only included superficial spreading melanoma, a subtype that is more predominant in NAM (5, 9).

Many histological features associated with better prognosis, such as lower Breslow thickness, less ulceration, and lower mitotic rate, were more frequent in NAM (5, 9).

### Table II. Univariate and multivariate analyses for overall survival and melanoma-specific survival

|                | Overall survival | Melanoma-specific survival |
|----------------|------------------|---------------------------|
|                | HR model 1 (univariate) | HR model 2 (multivariate) | HR model 3 (univariate) | HR model 4 (multivariate) |
| **Type**       |                   |                           |                           |                           |
| De novo melanoma | –                 | –                         | –                         | –                         |
| Naevus-associated melanoma | 0.64 (0.51–0.80, \( p < 0.001 \)) | 0.94 (0.75–1.18, \( p = 0.606 \)) | 0.67 (0.50–0.89, \( p = 0.005 \)) | 0.88 (0.66–1.18, \( p = 0.391 \)) |
| **Age, years** |                   |                           |                           |                           |
| <45.5          | –                 | –                         | –                         | –                         |
| 45.5–63.3      | 1.78 (1.37–2.31, \( p < 0.001 \)) | 1.35 (1.04–1.76, \( p = 0.024 \)) | 1.44 (1.08–1.91, \( p = 0.012 \)) | 1.00 (0.75–1.33, \( p = 0.989 \)) |
| >63.3          | 4.74 (3.76–5.99, \( p < 0.001 \)) | 3.19 (2.50–4.66, \( p < 0.001 \)) | 2.06 (1.57–2.72, \( p < 0.001 \)) | 1.24 (0.93–1.65, \( p = 0.148 \)) |
| **Sex**        |                   |                           |                           |                           |
| Female         | –                 | –                         | –                         | –                         |
| Male           | 1.93 (1.63–2.29, \( p < 0.001 \)) | 1.49 (1.25–1.79, \( p < 0.001 \)) | 1.91 (1.53–2.38, \( p < 0.001 \)) | 1.41 (1.12–1.78, \( p = 0.004 \)) |
| **AJCC**       |                   |                           |                           |                           |
| I              | –                 | –                         | –                         | –                         |
| II             | 3.80 (3.08–4.69, \( p < 0.001 \)) | 2.76 (2.23–3.42, \( p < 0.001 \)) | 7.01 (5.08–9.67, \( p < 0.001 \)) | 5.87 (4.22–8.15, \( p < 0.001 \)) |
| III            | 6.25 (5.09–7.67, \( p < 0.001 \)) | 5.28 (4.29–6.50, \( p < 0.001 \)) | 14.49 (10.71–19.59, \( p < 0.001 \)) | 13.06 (9.62–17.73, \( p < 0.001 \)) |
| **Melanoma location** |                   |                           |                           |                           |
| Trunk          | –                 | –                         | –                         | –                         |
| Lower limbs    | 0.85 (0.67–1.08, \( p = 0.193 \)) | 0.97 (0.76–1.25, \( p = 0.827 \)) | 0.70 (0.50–0.96, \( p = 0.028 \)) | 0.74 (0.53–1.03, \( p = 0.076 \)) |
| Upper limbs    | 0.69 (0.50–0.96, \( p = 0.027 \)) | 0.89 (0.64–1.23, \( p = 0.467 \)) | 0.57 (0.37–0.88, \( p = 0.012 \)) | 0.72 (0.46–1.12, \( p = 0.148 \)) |
| Head and neck  | 2.61 (2.08–3.28, \( p < 0.001 \)) | 1.71 (1.35–2.16, \( p < 0.001 \)) | 1.93 (1.42–2.63, \( p < 0.001 \)) | 1.46 (1.06–2.01, \( p = 0.020 \)) |
| Acral          | 2.41 (1.85–3.15, \( p < 0.001 \)) | 1.89 (1.44–2.48, \( p < 0.001 \)) | 2.46 (1.78–3.41, \( p < 0.001 \)) | 1.84 (1.32–2.57, \( p < 0.001 \)) |

Univariate and multivariate Cox regression analyses of overall survival (models 1 and 2, respectively), and univariate and multivariate Cox regression analyses of melanoma-specific survival (models 3 and 4, respectively). Factors included in the multivariate model were age, sex, American Joint Committee on Cancer (AJCC) stage and melanoma location.

HR: hazard ratio.
tion, lower mitotic index, less satellitosis, and a higher incidence of regression, are significantly more present in NAM than DNM. Furthermore, the proportion of patients classified as stage I by the AJCC were 72.5% and 60.3% for NAM and DNM, respectively. On the other hand, differences in SLNB status were not found when comparing both groups, which is consistent with other series, such as that by Lin et al. (9).

The phenotype of patients with NAM in our cohort was characterized by individuals with Fitzpatrick skin type I–II, red-blond-coloured hair and more than 50 naevi. This pattern has also been reported by other authors (14, 24, 25). Moreover, in the current study, patients with NAM were more likely to develop a second primary melanoma. Therefore, the surveillance and follow-up of these patients, with a higher melanoma risk, becomes especially important (26).

No significant differences between men and women were found in our cohort or in the literature (6). However, it was evident that NAMs were more frequent in younger patients. This could be explained by the fact that a higher number of naevi are more common in this age group (27, 28) as the number of naevi decreases as we get older. Another reason could be because melanomas in older individuals may result from cumulative sun damage (28). This could also explain why DNM were more frequent in locations with chronic sun exposure: upper and lower limbs, head and neck.

Recent molecular and genetic studies have described the mutational pathways in key melanocytic genes that convert benign naevi into melanomas (BRAFV600E, CDKN2A, TERT) (28, 29). Therefore, these findings suggest that the pathophysiological pathways of NAM and DNM could be different.

It is difficult to demonstrate whether a DNM was originally associated with a naevus. Some authors have explained the absence of naevus cells arguing that invasive melanoma cells tend to engulf them (7). This could explain the thicker Breslow index associated with melanomas without naevi cells (misclassified histologically as DNM) (7, 30, 31), but this error of categorization would not explain any of the demographic, clinical or genetic differences between NAM and DNM. Other authors defend the view that DNM could arise without any precursor lesion, either by the rapid accumulation of mutations or from a melanocyte which already harboured genetic alterations and then a proliferation-initiating mutation in MAPK pathway triggered the appearance of the melanoma (28). These differences described at an early tumoural stage, could help us classify NAM and DNM as 2 different melanoma types.

No differences in MC1R germline mutational status were detected between NAM and DNM patients. It is interesting that, although we have related NAM to fair phenotype, the main gene related with this feature, MC1R, was not predominantly found in the NAM group. In contrast, in the study by Martin-Gorgojo et al. (8) a significantly increased prevalence of MC1R variants was shown in patients with NAM (dysplastic type). These differences could be explained by the fact that no subgroup analysis was performed in the NAM group. Interestingly, the same authors did not find differences in the prevalence of somatic mutations in BRAF or NRAS genes between the 2 groups studied (8).

The primary objective of this study was to examine OS and MSS in both groups as its prognostic significance is still unclear in the literature. As early as the 1960s, Cochran (32) reported that the 5-year survival rates were not statistically different. In contrast, in the 1980s, Rhodes et al. (33) and Friedman et al. (34) suggested a more favourable survival rate in NAM. Kaddu et al. (35) and Weatherhead et al. (15) did not find survival differences. Although Shitara et al. (36) did not carry out a 5-year survival analysis, they suggested a more favourable prognosis for NAM based on the lower Breslow thickness as a surrogate marker. Lin et al. (9) reported no survival differences; however, their study group consisted of patients who consecutively underwent SLNB. Cymerman et al. (13) studied survival in 2 melanoma cohorts and found that NAM had better OS in univariate analysis, but this difference remained significant in only one cohort in their multivariate analysis. Finally, Martin-Gorgojo et al. (8) found a higher overall survival for patients with NAM, but multivariate adjustment showed that these differences were dependent on other characteristics rather than just histological association with a pre-existing naevus. Survival analysis in the current study using Kaplan–Meier curves and univariate analysis showed a significantly better OS and MSS in NAM than DNM. However, as with Martin-Gorgojo et al. (8), when we adjusted the presence of naevi cells with the other potential confounders in the multivariable analysis, no statistical significance was found in OS and MSS. Possible explanations for the difference in both OS and MSS in the univariable analysis could be that pathological misdiagnosis of a naevus as melanoma is more likely in NAM, or that invasion thickness could be overestimated in NAM because part of the naevus is added to the measurement, but based on the current data we believe that these differences are due to intrinsic characteristics of both melanoma types.

The findings of the current study support the theory that there are diverse genetic, molecular, and environmental factors in the pathways that can lead to the development of melanoma (12, 28). With the data from the current cohort differences in survival were found, but no difference in the multivariate analysis, so the difference found could be explained by the other clinicoopathological characteristics that are included in our model. Currently, differentiating NAM from DNM does not change our daily clinical practice, but we believe that differentia-
ting them may allow us a better understanding of both diseases, identifying different risk factors, leading to better primary and secondary preventive strategies. Future developments will include new tools, such as artificial intelligence or machine learning, which will allow us to integrate all this data and carry out more personalized staging and management.

Limitations

A limitation of this study is that it is a single-centre retrospective cohort study. However, we consider that the results could have good external validity since we included all patients with invasive melanoma and performed a prospective follow-up for a long period, thus decreasing the risk of bias.

Conclusion

Of melanomas, 22.86% were NAM and clinicopathological features associated with better prognosis are significantly more present in NAM than in DNM. However, OS and MSS of patients with NAM lose significance in the multivariable analysis. Despite this, giving all the data reported, although no differences in survival were found in the current study, it is appropriate to consider NAM and DNM as 2 different subtypes inside the large heterogeneous melanoma family.

ACKNOWLEDGEMENTS

The authors thank our patients and their families, who are the main reason for our studies; to the nurses from the Melanoma Unit at Hospital Clinic of Barcelona; and all the melanoma residents and fellows who play a fundamental role in our unit.

The study in the Melanoma Unit, Hospital Clinic, Barcelona, was partly supported by grants from Fondo de Investigaciones Sanitarias PI 12/00840, PI 15/00956, PI 15/00716 and PI 18/0959, Spain; by the Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras of the Instituto de Salud Carlos III, Spain, co-funded by “Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, Una manera de hacer Europa”; by the Agency for Management of University and Research Grants (AGAUR) 2014_SGR_603 and 2017_SGR_1134 of the Catalan Government, Spain; by a grant from “Fundació La Marató de TV3, 201331-30” Catalonia, Spain; by the European Commission under the 6th Framework Programme, Contract number LSHC-CT-2008-18702 (GenoMEL); by Centres de Recerca de Catalunya (CERCA) Programme/Generalitat de Catalunya; by a research grant from “Fundación Científica de la Asociación Española Contra el Cáncer” GCB15152978SOEN, Spain.

The sponsors had no role in the design and conduct of the study, in the collection, analysis, and interpretation of data; nor in the preparation, review, approval of the manuscript or in the decision to submit the manuscript for publication.

This study has been approved by the institutional review board.

All procedures performed in studies involving human participants were in accordance with the ethics standards of the institutional research committee and with the Declaration of Helsinki 1964 and its later amendments or comparable ethics standards.

REFERENCES

1. De Giorgi V, Gori A, Grazzini M, Rossari S, Oranges T, Longo AS, et al. Epidemiology of melanoma: is it still epidemic? What is the role of the sun, sunbeds, Vit D, betablocks, and others? Dermatol Ther 2012; 25: 392–396.
2. Śtumi M, Buljan M, Kolić M, Vulić M. Melanoma – clinical, dermatoscopy- and histopathological morphology characteristics. Acta Dermato-Venereol Croat 2014; 22: 1–12.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.
4. Clark WH, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions. Arch Dermatol 1978; 114: 732–738.
5. Bevona C, Goggin, Williams, Quinn, Timothy, Fullerton, Julie, Tsao, Hensin. Cutaneous melanomas associated with nevi. Arch Dermatol 2003; 139: 1620.
6. Pampena R, Kyrgidis A, Lallas A, Moscarella E, Argenziano G, Longo C. A meta-analysis of nevus-associated melanoma: prevalence and practical implications. J Am Acad Dermatol 2017; 77: 938–945.e4.
7. Marks B, Dorevitch AP, Mason G. Do all melanomas come from ‘moles’? A study of the histological association between melanocytic naevi and melanoma. Australas J Dermatol 1990; 31: 77–80.
8. Martin-Gorgojo A, Requena C, García-Casazo Z, Traves V, Kumr R, Nagore E. Dysplastic vs. common naevus-associated vs. de novo melanomas: an observational retrospective study of 1,021 patients. Acta Derm Venerol 2018; 98: 556–562.
9. Lin WM, Luo S, Muzikansky A, Lobo AZC, Tanabe KK, Sober AJ, et al. Outcome of patients with de novo versus nevus-associated melanoma. J Am Acad Dermatol 2015; 72: 54–58.
10. Stolz W, Schmoeckel C, Landthaler M, Braun-Falco O. Association of early malignant melanoma with nevocytic nevus. Cancer 1989; 63: 550–555.
11. Martin-Gorgojo A, Nagore E. Melanoma arising in a melano- cytic nevus. Actas Dermosifiliogr 2018; 109: 123–132.
12. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011; 24: 879–897.
13. Cymerman RM, Shao Y, Wang K, Zhang Y, Murzaku EC, Penn LA, et al. De novo vs nevus-associated melanomas: differences in associations with prognostic indicators and survival. J Natl Cancer Inst 2017; 109: djw121.
14. Pandeya N, Kvaskoff M, Olsen CM, Green AC, Perry S, Baxter C, et al. Factors related to nevus-associated cutaneous melanoma: a case–case study. J Invest Dermatol 2018; 138: 1816–1824.
15. Weatherhead SC, Hanifia M, Lawrence CM. Melanomas arising from naevi and de novo melanomas – does origin matter? Br J Dermatol 2007; 156: 72–76.
16. Podlipnik S, Carrera C, Sánchez M, Arquís P, Oلونdo ML, Vil- ana R, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Commit- tee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: a prospective cohort study. J Am Acad Dermatol 2016; 75: 516–524.
17. Riquelme-McLoughlin C, Podlipnik S, Bosch-Amate X, Riera-Monrig J, Barreiro A, Espinosa N, et al. Diagnostic accuracy of imaging studies for initial staging of T2b to T4b melanoma patients: a cross-sectional study. J Am Acad Dermatol 2019; 81: 1330–1338.
18. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Po-cock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007; 4: 27.
19. Terry M. Therneau, Patricia M. Grambsch. Modeling Survival Data: extending the Cox Model. New York: Springer, 2000.
20. Therneau TM, A package for survival analysis in R. 2020. [Accessed November 20, 2020] Available from: https:// CRAN-R-project.org/package=survival.
21. Kassambara A, Kosinski M, Biecek P. survminer: drawing survival curves using ’ggplot2’. 2019. [Accessed November 20, 2020] Available from: https://CRAN.R-project.org/package=survminer.

22. Harrison E, Drake T, Ots R. finalfit: quickly create elegant regression results tables and plots when modelling. 2020. [Accessed November 20, 2020]Available from: https://CRAN.R-project.org/package=finalfit.

23. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2020. [Accessed November 20, 2020] Available from: https://www.R-project.org/.

24. Holly EA, Kelly JW, Shpall SN, Chiu S-H. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 1987; 17: 459–468.

25. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005; 41: 28–44.

26. Echeverría B, Botella-Estrada R, Serra-Guillén C, Martorell A, Traves V, Requena C, et al. Increased risk of developing a second primary cutaneous nevus-associated melanoma in patients previously diagnosed with the disease. Actas Dermosifiliográficas Engl Ed 2010; 101: 710–716.

27. Mackie RM, English J, Aitchison TC, Fitzsimons CP, Wilson P. The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population. Br J Dermatol 1985; 113: 167–174.

28. Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer 2016; 16: 345–358.

29. Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med 2015; 373: 1926–1936.

30. Garcia-Cruz A, Florez A, de la Torre-Fraga C, Cruces Prado M. Observational cross-sectional study comparing Breslow thickness of melanoma arising from naevi and melanoma de novo. Br J Dermatol 2009; 161: 700–702.

31. Manrique-Silva E, Reyes-García D, Folgado B, Martín-Gorgojo A, Traves V, Requena C, et al. The proportion of nevus-associated invasive melanoma differs with Breslow thickness: a cross-sectional study of 1087 cutaneous melanomas. J Am Acad Dermatol 2019; 81: 852–854.

32. Cochran AJ. Histology and prognosis in malignant melanoma. J Pathol 1969; 97: 459–468.

33. Rhodes AR, Sober AJ, Day CL, Melski JW, Harrist TJ, Mihm Jr Martin C, et al. The malignant potential of small congenital nevocellular nevi: an estimate of association based on a histologic study of 234 primary cutaneous melanomas. J Am Acad Dermatol 1982; 6: 230–241.

34. Friedman RJ, Rigel DS, Kopf AW, Lieblich L, Lew R, Harris MN, et al. Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi. Arch Dermatol 1983; 119: 455–462.

35. Kaddu S, Smolle J, Zenahlik P, Hofmann-Wellenhof R, Kerl H. Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis. Melanoma Res 2002; 12: 271–278.

36. Shitara D, Nascimento MM, Puig S, Yamada S, Enokihara MMSS, Michalany N, et al. Nevus-associated melanomas: clinicopathologic features. Am J Clin Pathol 2014; 142: 485–491.